ReviewInternational journal of nanomedicine2026
Extracellular Vesicles in Drug Delivery: From Quality Assurance to Therapeutic Application.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exosomes in corneal diseases: advances in diagnosis and therapy.Frontiers in cell and developmental biology · 2026Review
- EV-Mediated Oncogenic Regulation in Lung Cancer and Clinical Translation: From Liquid Biopsy to Targeted Delivery Systems.International journal of nanomedicine · 2026Review
- Extracellular Vesicles in Pancreatic Cancer Function and Potential Clinical Applications.OncoTargets and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing optimal drug delivery carriers to enhance the pharmacokinetics of therapeutic agents and mitigate toxicity to normal cells remains a pivotal focus in medical research. Extracellular vesicles (EVs) have emerged as a highly promising platform for drug delivery, owing to their unique biological properties. Through intrinsic biogenesis pathways, EVs can selectively encapsulate genetic material, proteins, cytokines, and other bioactive components from donor cells. They subsequently mediate intercellular communication and regulate target cell behavior via humoral transport, surface protein interactions, membrane fusion, and other mechanisms-biological features that lay the foundation for their potential in therapeutic delivery. In recent years, EVs have attracted tremendous research interest due to their excellent biocompatibility, nanoscale size, low immunogenicity, facile modifiability, and versatile capacity to load various therapeutic agents. In this review, we analyse strategies for improving the quality control of drug-loaded EVs across multiple dimensions, specifically including the selection of EVs sources, control of isolation and purification, control of drug-loading strategies, and evaluation strategies after EVs drug loading, we also report the latest preclinical and clinical studies on the use of EVs as drug delivery systems for small-molecule drugs, nucleic acids, and proteins in disease treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.